mRNA Therapeutics CDMO Market To Reach $14.75 Billion By 2033

mRNA Therapeutics Contract Development & Manufacturing Organization Market Growth & Trends

The global mRNA therapeutics contract development & manufacturing organization market size is estimated to reach USD 14.75 billion by 2033, expanding at a CAGR of 15.22% from 2025 to 2033, according to a new report by Grand View Research, Inc. Growing technological advancements in mRNA and cellular delivery systems, coupled with their cost effectiveness, manufacturing simplicity, and ability to target previously undruggable pathways, have limitless potential to revolutionize medicine. This could represent lucrative growth opportunities for the market. Increasing R&D investments to develop mRNA therapeutics and a strong product pipeline are also propelling the market’s growth. For instance, Moderna shared that R&D expenses for the fourth quarter of 2023 increased by 16% to USD 1.4 billion compared to the same quarter of 2022.

The R&D spending was driven by increased clinical manufacturing activities, with the company’s Cytomegalovirus (CMV) vaccine, RSV vaccine, and combination vaccine against COVID-19 & flu, as well as its individualized neoantigen therapy. Such factors are expected to boost research efforts in mRNA therapeutics. In addition, developing novel therapeutics to address unmet medical needs is altering the product market. The rise in molecular complexity drives the need for in-depth knowledge in research and manufacturing services, as well as the technology to enable sustainable expression and scale-up of novel molecular formats. Platform technologies, such as those for bioconjugation or the creation of bispecific antibodies, can drastically shorten development and production times, and customers are looking for skilled CDMOs who can assist them shorten the time to market and reducing investment risk. Consequently, the need for CDMOs to design and produce goods for the pharmaceutical and biotechnology industries is growing exponentially.

 Request a free sample copy or view report summary: mRNA Therapeutics Contract Development & Manufacturing Organization Market Report

mRNA Therapeutics Contract Development & Manufacturing Organization Market Report Highlights

• The viral vaccines segment accounted for the largest share in 2024. Growth in the segment can be attributed to the rising availability and launch of various vaccines for the treatment of viral infection (COVID-19)

• The infectious diseases segment held the largest market share in 2024 due to the growing incidence of infectious diseases, several advantages of mRNA vaccine over conventional vaccines, emerging clinical studies & pipeline analysis, and increasing collaboration between pharmaceutical companies & CDMO for production

• The biotech companies end-use segment dominated the market and accounted for a share of more than 62.34% in 2024. The segment growth is driven by increasing strategic initiatives, such as partnerships & collaborations with CDMOs, to manufacture mRNA vaccines

• The mRNA therapeutics contract development & manufacturing organization market in Asia Pacific is expected to grow at a significant CAGR over the forecast period. Due to the rising number of pharmaceutical companies and contract manufacturing organizations in developing countries like India and China, Asia Pacific is likely to overtake Europe and North America in the near future.

mRNA Therapeutics Contract Development & Manufacturing Organization Market Segmentation

Grand View Research has segmented the global mRNA therapeutics contract development & manufacturing organization market based on indication, application, end use, and region:

mRNA Therapeutics CDMO Indication Outlook (Revenue, USD Million, 2021 - 2033)

• Infectious Diseases

• Metabolic & Genetic Diseases

• Cardiovascular & Cerebrovascular Diseases

mRNA Therapeutics CDMO Application Outlook (Revenue, USD Million, 2021 - 2033)

• Viral Vaccines

• Protein Replacement Therapies

• Cancer Immunotherapies

mRNA Therapeutics CDMO End Use Outlook (Revenue, USD Million, 2021 - 2033)

• Biotech Companies

• Pharmaceutical companies

• Government & Academic Research Institutes

mRNA Therapeutics CDMO Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Denmark

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Thailand

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

list of Key Players in the mRNA Therapeutics CDMO Market

• Danaher (Aldevron)

• Biomay AG

• Bio-Synthesis, Inc.

• eTheRNA

• Kaneka Eurogentec S.A.

• TriLink BioTechnologies

• ApexBio Technology

• BioNTech SE

• Biocina

• Lonza

• Recipharm AB

• Novo Holdings (Catalent, Inc.)

• Samsung Biologics